Group 1 - The core viewpoint of the article highlights a collective decline in Hong Kong's innovative drug concept stocks on September 4, with significant drops in various companies [1] Group 2 - Zai Lab experienced a decline of over 10% [1] - Hengrui Medicine, Genscript Biotech, and Cloudmed fell by more than 5% [1] - WuXi AppTec dropped over 4%, while Innovent Biologics, WuXi Biologics, and Hansoh Pharmaceutical decreased by more than 3% [1]

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion of Chinese pharmaceutical companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring nearly a hundred executives from listed companies, including chairpersons, CEOs, and industry leaders [4]. Morning Sessions - The morning session on September 4 will include a keynote speech and several roundtable discussions focusing on topics such as the global expansion of Chinese pharmaceutical companies and the search for the next billion-dollar drug [4][5]. - Notable discussions will include: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Bomb" [4]. Afternoon Sessions - The afternoon will feature discussions on future disease areas and technologies worth exploring for pharmaceutical assets going abroad, as well as the new cycle of Chinese innovative drugs under global competition [5][6]. - Additional topics will cover advancements in drug development platforms and the emerging field of brain-machine interfaces [6]. TMT Forum - The TMT (Technology, Media, and Telecommunications) forum will also take place, discussing AI's impact on various industries, including gaming and healthcare [7][8]. - Key topics will include AI innovations in mobile internet ecosystems and the future of AI in healthcare [7]. Pharmaceutical Sub-Forum - The pharmaceutical sub-forum will address topics such as ADC technology exploration, probiotic delivery systems, and the future development paths of dual antibodies and XDC [8]. - Discussions will also focus on the integration of medical insurance and the innovative practices in building a multi-level medical security system in China [8].

Group 1 - The small molecule GLP-1RA market is expected to provide new growth opportunities for weight loss and diabetes management, with Eli Lilly's Orforglipron leading the global development [1][2] - Orforglipron has completed three global Phase III clinical trials, confirming its safety, although its weight loss efficacy did not meet market expectations [2][3] - Domestic companies such as Hengrui Medicine, East China Pharmaceutical, and Genscript Biotech are actively developing small molecule GLP-1RA pipelines, with several products entering late-stage clinical trials [3] Group 2 - The pharmacokinetic characteristics of small molecule GLP-1RAs may significantly impact their efficacy, prompting companies to explore new formulations to enhance solubility [4] - Genscript's ASC30 shows higher drug exposure and receptor binding efficacy compared to Orforglipron, indicating potential for better clinical outcomes [4]

青岛银行(03866.HK)大股东拟将持股比例增持到19.00%至19.99% 青岛银行(03866.HK)公告，公司于近期获本行大股东青岛国信产融控股（集团）有限公司通知，其计划 通过二级市场交易的方式增持本行股份，增持后国信产融控股及其一致行动人的合计持股比例将达到 19.00%至19.99%之间，本次增持计划的实施期限为自本公告披露之日起6个月内。增持计划将避免在本 行定期报告静默期、重大事项敏感期等期间实施。 计划增持主体为青岛国信产融控股（集团）有限公司。截至本公告披露之日，国信产融控股持有本行 654,623,243股A股，占本行股份总数的11.25%；其一致行动人青岛国信金融控股有限公司持有本行 217,847,280股H股，占本行股份总数的3.74%；其一致行动人青岛国信资本投资有限公司持有本行650股 A股，占本行股份总数的0.00001%。综上，国信产融控股及其一致行动人合计持有本行股份872,471,173 股，占本行股份总数的14.99%。 【今日焦点】 蔚来-SW(09866.HK)第二季度经调整净亏损环比下降34.3% 预计第三季度总交付量增长40.7%至47.1% 新意网集团(0 ...

Core Viewpoint - The company is set to present clinical data for ASC30, an oral small molecule GLP-1 receptor agonist, at the 61st European Association for the Study of Diabetes (EASD) annual meeting in Vienna, Austria, highlighting its potential as a differentiated treatment for obesity [1] Group 1: Clinical Research and Development - ASC30 is currently undergoing a 28-day multiple ascending dose study (NCT06680440) [1] - The drug is characterized as a new chemical entity (NCE) with unique properties that allow for both oral and subcutaneous administration [1] - The compound is protected by patents in the U.S. and globally, with patent protection lasting until 2044, excluding any extensions [1] Group 2: Company Leadership and Vision - Dr. Wu Jinzi, the founder, chairman, and CEO of the company, expressed confidence that the efficacy and safety data presented will position ASC30 as a promising option for obesity treatment [1]

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), will present data on ASC30, an oral small molecule GLP-1 receptor agonist, at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria [1] Summary by Relevant Sections Clinical Data Presentation - The presentation will include findings from a 28-day multiple ascending dose study (NCT06680440) of ASC30, highlighting its superior weight loss effects in obese subjects [1] - The abstract title for the discussion is "ASC30, an oral GLP-1R biased small molecule agonist shows superior weight loss effects in obese subjects: a 28-day multiple ascending dose study" [1] Event Details - The discussion will take place on September 16, 2025, from 12:00 to 13:00 (Central European Summer Time) [1] - The report number for this presentation is 827 [1] Company Perspective - Dr. Wu Jinzi, founder, chairman, and CEO of the company, expressed anticipation for showcasing the clinical data at the EASD meeting, believing that the efficacy and safety data will position ASC30 as a differentiated treatment option for obesity [1]

Core Viewpoint - The company is set to present clinical data for ASC30, an oral small molecule GLP-1 receptor agonist, at the 61st European Association for the Study of Diabetes (EASD) annual meeting in Vienna, Austria, highlighting its potential as a differentiated treatment for obesity [1] Company Summary - The CEO of the company, Dr. Wu Jinzi, expressed optimism about the clinical efficacy and safety data for ASC30, suggesting it could become a unique solution for obesity treatment [1] - ASC30 is a new chemical entity (NCE) with both oral and subcutaneous administration capabilities, supported by patent protection in the U.S. and globally until 2044, excluding any patent extensions [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 自願性公告 歌禮將在第61屆歐洲糖尿病研究協會(EASD)年會上報告ASC30 口服小分子GLP-1R激動劑28天多劑量遞增研究結果 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）宣布，將在奧地利維也納舉行的第61屆歐洲 糖尿病研究協會(EASD)年會上的簡短口頭討論中報告ASC30口服小分子GLP-1受 體(GLP-1R)激動劑28天多劑量遞增研究(NCT06680440)數據。 簡短口頭討論細節 「我們期待在今年的EASD年會上向業界展示ASC30口服片的臨床數據，」歌禮創 始人、董事會主席兼首席執行官吳勁梓博士表示，「我們相信這些療效和安全性數 據 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 歌禮製藥有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 7,000,000,000 | USD | | 0.0001 | USD | | 700,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 7,000,000,000 | USD | | 0.0001 | USD | | 700,000 | 本月底法定/註冊股本總額： USD 700,000 FF3 ...

Core Viewpoint - The Chinese innovative pharmaceutical sector has transformed from being overlooked to becoming highly sought after, driven by a surge in business development (BD) transactions that have led investors to reassess the value of innovative drugs in China [1][8]. Group 1: BD Transactions and Market Dynamics - The recent surge in BD transactions, such as the $60.5 billion collaboration between 3SBio and Pfizer, and the $120 billion deal between Hengrui Medicine and GlaxoSmithKline, has significantly influenced investor perceptions and valuations in the innovative drug sector [1][9]. - In the first half of 2025, there have been over 50 BD transactions in China's innovative drug sector, with a total value exceeding $48 billion [9]. - The excitement around BD transactions has revitalized both the secondary and primary markets, leading to a resurgence of investor confidence in the pharmaceutical sector [2][4]. Group 2: IPO Activity and Investor Sentiment - The hot secondary market has prompted investors to actively seek IPO opportunities, with over 50 pharmaceutical companies applying for listings in Hong Kong in the first half of 2025 [11]. - Many innovative drug companies are currently looking for cornerstone investors as they prepare for IPOs, indicating a strong desire to capitalize on the favorable market conditions [11][12]. - The increase in BD transactions and the resulting stock price surges have created a favorable environment for investors to exit their investments, thereby enhancing their credibility with limited partners (LPs) [14]. Group 3: Valuation Trends and Investment Strategies - The valuation of innovative drug companies has adjusted to more reasonable levels, with companies completing Phase II clinical trials now valued between $1 billion and $1.5 billion, compared to previous valuations of $2 billion to $5 billion [20]. - Some innovative drug companies have already begun to raise their valuations in response to the improving market conditions, reflecting a competitive investment landscape [21]. - Investment firms are expanding their teams to capture opportunities in the recovering pharmaceutical market, with some actively recruiting analysts and vice presidents in the healthcare sector [22].